Trevena, Inc. (NASDAQ:TRVN – Get Free Report)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.01 and traded as low as $0.01. Trevena shares last traded at $0.0112, with a volume of 1,756 shares.
Trevena Stock Performance
The firm has a market cap of $10,740.80, a P/E ratio of -0.00 and a beta of -0.55.
Trevena Company Profile
Trevena, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligand G protein-coupled receptor (GPCR) selective medicines. By leveraging its proprietary bias-ligand technology platform, Trevena aims to create therapies that preferentially activate beneficial signaling pathways while minimizing engagement of pathways linked to adverse effects. The company’s research efforts target areas of high unmet medical need, including pain management, cardiometabolic disorders and central nervous system conditions.
The company’s lead compound, oliceridine (also known by its brand name OLINVEO), is a G protein-biased μ-opioid receptor agonist designed for the treatment of moderate to severe acute pain in the hospital setting.
Read More
- Five stocks we like better than Trevena
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
